OS Therapies IncOSTX
Price (close)
$1.66
Market cap
$76.6M
P/E
—
Revenue (TTM)
—
Net income
-$39.4M
Dividend yield
—
1-year total return
-21.3%
Net margin
—
Revenue growth
—
Debt / equity
—
What OS Therapies Inc does.
company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. Our
mission is to address the significant need for new treatments in cancers of the bone in children and young adults. Osteosarcoma is an
extremely challenging and often aggressive cancer that has particular treatment challenges due to its location, changing genotypes and
Revenue and profit, by fiscal year.
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net income | — | -$7.8M | -$8.9M | -$28.8M |
| Free cash flow | — | — | — | -$14.7M |
More on OSTX.
- OS Therapies Inc summary
- OS Therapies Inc financial statements
- OS Therapies Inc key metrics
- OS Therapies Inc health scores and style box
- OS Therapies Inc earnings
- OS Therapies Inc dividends
- OS Therapies Inc valuation
- OS Therapies Inc ownership and insiders
- OS Therapies Inc peers
Figures from OS Therapies Inc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.